SynthesisFrontiers in oncology2021

First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Qiang Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.